INTRODUCTION PATIENTS AND METHODS
Ciprofloxacin is a broad-spectrum fluoroquinolone with in vitro activity against Gram-positive and Gram-negative organisms, including Pseudomonas aeruginosa.t-: The clinical efficacy and safety of ciprofloxacin have been established in studies performed worldwide over the past decade for the treatment of urinary tract infections, lower respiratory tract infections, nosocomial pneumonia, skin and skin structure infections, bone and joint infections, intraabdominal infections, acute sinusitis, chronic bacterial prostatitis, and empiric therapy for febrile neutropenic patients, respectively." In the treatment of lower respiratory tract infections, a meta-analysis found ciprofloxacin to have superior clinical efficacy and bacteriological eradication rates compared with other antibacterial agents against Haemophilus influenzae and Streptococcus pneumoniae:" In a review of 37 clinical studies involving 3247 patients with lower respiratory tract infections, however, there was no significant difference between ciprofloxacin and other agents in the overall rate of clinical success, and also no significant difference in the bacterial eradication rates against S. pneumoniae, H. influenzae and Moraxella catarrholis:"
This study investigated the efficacy and safety of intravenous ciprofloxacin in eight Japanese patients with lower respiratory tract infections and determined pharmacokinetic parameters in one patient. The investigation was carried out as part of a multicentre trial in the treatment of chronic respiratory tract infections; the pharmacokinetic analysis contributed to a multicentre, double-blind study comparing ceftazidime with ceprafloxacin in the treatment of bacterial pneumonia in Japan.
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PATIENTS
Patients with bacterial signs and symptoms of lower respiratory tract infections were eligible to enrol in this study. Informed consent was obtained from all patients prior to enrolment. Exclusion criteria included pregnancy, severe liver and/or renal dysfunction or a history of allergy to fluoroquinolones.
TREATMENT AND EVALUATION
Intravenous ciprofloxacin 200 mg (Bayer AG, Leverkusen, Germany) was administered every 8 h (tid) or 12 h (bid) and 300 mg every 12 h; treatment lasted 3 -14 days. Dose and duration of treatment was determined by each patient's baseline condition. Clinical efficacy was evaluated at the end of the treatment period based on signs and symptoms, clinical laboratory data and chest radiograph. Sputum for microbiological examination was obtained from the patients before and after treatment to determine baseline organisms. Safety was assessed by recording subjective and objective adverse events reported by the patient and by evaluation of laboratory findings.
PHARMACOKINETIC ANALYSIS
In one patient with bronchiectasis treated with intravenous ciprofloxacin 300 mg, pharmacokinetic evaluation of ciprofloxacin in blood and sputum samples was also determined. Blood samples were collected before and at 0.5, 1, 2, 3,4 and 6 h after the first dose of ciprofloxacin 300 mg and, sputum samples were obtained before and at 0.5, 1, 2, 3, 4, 6, 7 and 8 h after the first treatment. Blood samples were immediately centrifuged (3000 g) for 10 min at room temperature. Both serum and sputum were stored at -80°C until determination of M Obmichi, Y Hirago
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ciprofloxacin using high-performance liquid chromatography (HPLC). Aliquots (10 ul) of serum and sputum, respectively, were applied to 3.9 x 300 mm column filled with uBondpak C18 (Waters Corp., Milford, MA, USA). Ciprofloxacin was measured by fluorescence (emission wavelength 445 nrn, excitation wavelength 278 nm), according to the method of Kadowaki et aJ. 6 The lower limit of quantification was 0.025 ug/rnl. Pharmacokinetic parameters were calculated by the two-compartment model based on a simulated pharmacokinetic profile using TOPFIT Version 2.0 (VCH Publishers, Inc., New York, NY, USA).
RESULTS
Eight patients presented with the following lower respiratory tract infections: pneumonia (n = 4), bronchiectasis with infection (n = 2), previous pulmonary tuberculosis with infection (n = 1) and diffuse panbronchiolitis (n = 1). All patients exhibited signs and symptoms of bacterial infection, such as purulent sputum, cough, elevation of C-reactive protein (CRP), neutrophilia and infiltration on chest radiograph. Patient demographic data including underlying disease and diagnosis are indicated in Table 1 .
CLINICAL EFFICACY
Of four patients with chronic respiratory infections (patient numbers 1 -4), three improved clinically after 9.5 -11 days of treatment (Table 2) . Similarly, three of the four patients with pneumonia recovered based on chest radiograph findings, fever reduction and decreased inflammatory marker concentrations to within the normal range (Tables 2 and 3) .
One of the patients with bronchiectasis, however, did not respond to intravenous ciprofloxacin 300 mg every 12 h in treatment lasting 14 days. On day 3 of medication, the white blood cell and CRP count returned to 299 normal compared with pre-treatment values (6800/mm 3 versus 13 400/mm 3 and 8.31 mg/dl versus 20.30 mg/dl, respectively), but the clinical symptoms of fever, cough and sputum production worsened on day 7. In addition, although H. influenzae was eradicated after 14 days of treatment, this patient did not recover clinically until after administration of a t-month combination regimen of panipenem/ betamipron, isepamycin, erythromycin and sparfloxacin.
BACTERIOLOGICAL ERADICATION
Bacteriological eradication was confirmed in three of six patients in whom a baseline organism was identified; however, in the two patients in whom no baseline bacteria were isolated clinical improvement was confirmed in one patient ( Table 2 ).
ADVERSE EVENTS
No clinically relevant adverse events were reported by any patient or the investigator during the study period.
CLINICAL LABORATORY DATA
A slight increase in liver function tests was observed post-treatment in two patients: serum glutamate pyruvate transferase (SGPT) increased from 32 lUll to 66 lUll in one patient. In another patient who also exhibited slight eosinophilia, SGPT increased from 15 lUll to 74 lUll and serum glutamate oxaloacetate transferase increased from 23 lUll to 70 lUll (Table 3 ). These abnormal laboratory values decreased to normal levels immediately after completion of ciprofloxacin administration.
PHARMACOKINETICS
The ciprofloxacin serum and sputum concentrations analysed in one patient who received intravenous ciprofloxacin 300 mg are .shown in Table 4 . The maximum ciprofloxacin serum concentration of M Ohmichi, Y Hiraga In one patient with bronchiectasis, the serum and sputum concentrations of ciprofloxacin were determined and this resulted in a ratio of approximately 1:0, which coincides with data reported in a recent review. 7 Intravenous ciprofloxacin 300 mg every 12 h showed clinical efficacy in the treatment of pneumonia, including pneumococcal pneumonia, in three of four patients in this study, although its in vitro activity is less potent than that of novel quinolone compounds, e.g. trovafloxacin, grepafloxacin, sparfloxacin and levofloxacin. In one of the patients in whom neither a baseline organism could be identified nor a clinical response obtained to 4 days treatment did, however, respond to a 20-day regimen of concomitant panipenem/ betamipron, fluconazole and erythromycin.
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No adverse events were reported or detected in this trial and only slight abnormalities in liver function tests were found, which resolved without treatment after completion of ciprofloxacin administration. One patient showed eosinophilia but this was not clinically relevant.
In conclusion, this study investigated the efficacy and safety of intravenous ciprofloxacin in patients with lower respiratory tract infections and demonstrated clinical efficacy in six of eight patients. Intravenous ciprofloxacin was well tolerated and is effective in the treatment of lower respiratory tract infections.
